

ISIGNTHIS

Zusammenfassung der ASX-Meldung vom 31. Januar 2020

31 Januar 2020

iSignthis berichtet über die Highlights und die Ergebnisse des letzten Quartals

- Der Umsatz ist im 4. Quartal um 79% von 8,58 Mio. AUD im dritten Quartal 2019 auf 15,35 Mio. AUD im 4. Quartal 2019 gestiegen.
- Die Zahlungseingänge sind um 88% von 8,33 Mio. AUD im dritten Quartal 2019 auf 15,70 Mio. Euro im 4. Quartal 2019 gestiegen.
- Die Cash-Position des Unternehmens ist um 43% von 12,38 Mio. AUD im dritten Quartal 2019 auf 17,70 Mio. AUD im 4. Quartal 2019 gestiegen.
- Die Kundengelder sind um 24% von 77,74 Mio. AUD im dritten Quartal 2019 auf 96,18 Mio. AUD im 4. Quartal 2019 gestiegen.
- Die Geldeingänge im gesamten Geschäftsjahr 2019 belaufen sich auf 31,44 Mio. AUD.
- Das abgelaufene Quartal ist zum 3. mal in Folge positiv
- Es handelt sich um das erste profitable Betriebsjahr seit Betrieb des Tier 1 Netzwerkes.
- Das Unternehmen wächst weiterhin organisch, Finanzierungsrunden sind derzeit nicht erforderlich
- Die Kosten im 4. Quartal waren höher als erwartet.
- Es wurden im abgelaufenen Quartal 750.000 AUD in Forschung & Entwicklung für den Einsatz

6-Monats-Chart iSignthis, ASX

6 Monate ▾



| | |
|------------------|-----------------------------------|
| Börsen: | ASX & FRA |
| Code: | ASX: ISX / FRA:TA8 |
| Marktk. | 1,17 Mrd. AU\$ / 699,50 Mio. € |
| GICS ind. group: | Software & Services |

Kennzahlen Q4 bzw. Jan-Dez 2019

| | |
|-----------------------|--|
| Umsatz: | 15,7 Mio. AU\$ (Q4/2019); 31,4 Mio. AU\$ (2019) |
| Net Cash (OpA) | 3,5 Mio. AU\$ (Q4/2019); 4,3 Mio. AU\$ (2019) |
| Cash Position | 17,7 Mio. AU\$ (31.12.2019) |

OpA: Net cash from / (used in) operating activities

Für diese deutschsprachige Zusammenfassung der ASX-Meldung von iSignthis wird keine Haftung übernommen. Es gilt die Originalmeldung von iSignthis, abrufbar auf der Webseite der Australian Security Exchange unter www.asx.com.au

All information and advice is confidential and for the private information of the person to whom it is provided and is provided without any responsibility or liability on any account whatsoever on the part of this firm or any member or employee thereof.

This paper is a marketing communication only and does not constitute nor does it contain an offer or invitation to buy or subscribe for securities in any of the companies listed, nor is it an inducement to make an offer or invitation with respect to any of the securities within. This information is intended solely for professional investors in the capital markets. The paper is not meant for private investors or other groups and is not to be forwarded to them. Please take note of this disclaimer.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

DR REUTER INVESTOR RELATIONS

SPEZIALIST IN INVESTOR RELATIONS WORK ON THE EUROPEAN CAPITAL MARKETS
FRIEDRICH EVERT ANLAGE 35-37
TOWER 185
60327 FRANKFURT
DR. EVA REUTER, TEL. +49 251 7 32 862
E.REUTER@DR-REUTER.EU

neuer Produkte investiert.

- Die Handelsstreitigkeiten mit der ASX Ltd haben das Wachstum verlangsamt und das EBIT beeinflusst.

Aus dem Quartalsbericht

- Der operative Cash Flow aus dem abgelaufenen Quartal beläuft sich auf 3,5 Mio. AUD. Innerhalb der letzten 12 Monate belief sich der operative Cash Flow auf 4,3 Mio. AUD.
- Die Zahlungsabflüsse aus Investitionen belaufen sich auf -655.000 AUD. Innerhalb der letzten 12 Monate beliefen sich die Zahlungseingänge aus Investitionen auf - 691.000 AUD.
- Die Zahlungseingänge aus Finanzgeschäften belaufen sich auf 2,4 Mio. AUD. Innerhalb der letzten 12 Monate beliefen sich die Zahlungseingänge aus Finanzgeschäften auf 5,6 Mio. AUD.
- Die Barmittelbestände zum 31. Dezember 2019 belaufen sich auf 17,7 Mio. AUD.

Zum vollständigen Quartalsbericht von iSighthis geht es [hier](#).

DR REUTER INVESTOR RELATIONS

SPEZIALIST IN INVESTOR RELATIONS WORK ON THE EUROPEAN CAPITAL MARKETS
 FRIEDRICH EVERT ANLAGE 35-37
 TOWER 185
 60327 FRANKFURT
 DR. EVA REUTER, TEL. +49 251 7 32 862
 E.REUTER@DR-REUTER.EU

Disclaimer

The information and opinions given in this note have been drawn up by Dr. Reuter Investor Relations. This note has been exclusively published for informative purposes and represents neither a request, quotation nor a recommendation for buying or selling investment instruments or for effecting other transactions. Moreover, neither this publication nor its information forms the basis for a contract or a commitment of any kind. Any investment in shares, loans and options is faced with risks.

The information and data come from sources which Dr Reuter Investor Relations considers to be reliable. However, Dr Reuter Investor Relations do not assume any responsibility for the correctness and completeness of the information and data. Neither the writer nor Dr. Reuter Investor Relations are liable for losses or damage of any kind in connection with the content of this information brochure. By accepting this document you agree to the provisions previously noted as being mandatory for the recipient. Share prices can vary and corporate value can rise/fall. Any reference to the previous trend in value is not necessarily an indicator of developments to come. Rates of exchange can adversely affect the value trend, price and earnings of any company mentioned here. Reference is also made here to possible political, economic, credit, foreign exchange and market risks. Investment in any of the companies mentioned should only be done after studying the most recent brochure and other company/market information available and /or obtaining appropriate professional advice. Corporate brochures can be obtained from the companies in question. The reader should evaluate any investment in any of the companies mentioned there in the light of their own professional advice, circumstances and investment goals. The recommendation of Dr Reuter Investor Relations - in the event of any investments - is to consult a qualified professional consultant as to the specific financial risks and the statutory, official, credit, fiscal and settlement-induced consequences. It is quite possible that the issuers of the securities mentioned here have acted at variance to the facts of the case specified herein without Dr. Reuter Investor Rela-

tions being aware of this development.

In drawing up this paper, the following conflicts of interest cannot be categorically ruled out:

1. The companies specified may be Dr. Reuter Investor Relations customers and this publication is undertaken as part of the investor relations service package.
2. This publication was presented to the companies specified before publication and may have been changed at the company's request.
3. Dr Reuter Investor Relations and/or an affiliated company or the writer may have long or short positions in the companies specified.

This paper includes the following possible conflicts of interest: iSignthis is a customer of Dr. Reuter Investor Relations.

Some of the following detailed statements are based on translations of corporate news and company documentation. No liability is assumed for the translations. Please refer to the original English notifications and original documents.

Disclaimer United States:

1. NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.
2. This news release does not constitute an offer to sell or other solicitation of an offer to buy any ordinary shares within the United States. The ordinary shares have not been offered and will not be registered under the United States Securities Act of 1933, as amended (the "1933 Act"), or any state securities laws. Accordingly, the ordinary shares may not be offered or sold in the United States or to U:S Persons (as such terms are defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws or an exemption from such registration is granted.
3. Information and investment comments are independently and thoroughly researched and believed correct. No guaranty of absolute accuracy can be given however. Investment decisions are fully made for own risk.